$16.31+0.58 (+3.69%)
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. in the Healthcare sector is trading at $16.31 with a market capitalization of $1.8B. Wall Street consensus targets $33.94 (16 analysts), implying a +108.1% move over the next 12 months. The stock is currently near its 52-week low of $13.18, remaining 32.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclona...
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced stocks to buy for the next 3 years. On May 6, Viridian Therapeutics announced the pricing of upsized concurrent public offerings totaling $350 million in aggregate gross proceeds. The financing consists of $225 million in 1.75% convertible senior notes due 2032 and an equity […]
Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
Viridian Therapeutics recently reported positive topline results from its REVEAL‑2 phase 3 trial of elegrobart in chronic thyroid eye disease, while also completing US$125,000,014 of common stock and US$225,000,000 of convertible note offerings to support its pipeline and launch preparations. The company is now positioned with two late-stage IGF‑1R antibody programs for thyroid eye disease, veligrotug nearing an FDA decision and elegrobart advancing toward a planned 2027 biologics license...
A week ago, Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) came out with a strong set of first-quarter numbers that could...
Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.